ArticleSleep & breathing = Schlaf & Atmung2026
A 10-year nationwide analysis of nocturnal device prescriptions for sleep apnea in France.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleep apnea has become an increasingly important condition to address, given its growing prevalence in the general population with positive airway pressure (PAP) and mandibular advance device (MAD) as the main treatment. This study aims to describe the evolution of PAP and MAD prescriptions in France over the past ten years, the associated healthcare costs, and the changing characteristics of both beneficiaries and prescribers.
methodsThis study is based on open access reimbursement data from the national health care system (Open LPP) between 2014 and 2023, which provide data on all PAP and MAD prescriptions within the French population.
resultsThe number of PAP prescriptions has increased by an average of 16% per year, rising from 986,784 in 2014 to 3,362,040 in 2023. Despite reductions in reimbursement rates, healthcare expenditures have doubled, reaching 934 million euros in 2023 for PAP. Private care specialists contributed the most to the increase in prescriptions. Regarding beneficiaries, 64% of prescriptions in 2023 were for male patients compared to 70% in 2014. Meanwhile, adherence to PAP therapy have decreased with 67.6% of patients having an adherence > 4 h/day in 2018 vs. 63.6% (p = 0.03). MAD prescriptions in France increased from 8,110 in 2014 to 29,546 in 2023, representing an average annual growth of 17%.
conclusionPAP and MAD prescriptions have risen markedly over the past decade in France, alongside increasing healthcare expenditures and shifting patterns of prescribers and beneficiaries.
Indexed as
Identifiers
42714748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.